Institut Jules Bordet — Clinical Trial Site

248 Registered trials

128 Currently recruiting

Organisation

Institut Jules Bordet

Location

Anderlecht, Belgium

Identifier

ORG-100006103

Address

Mijlenmeersstraat 90, 1070, Belgium

Departments

-
#1006: oncology
#2033: Hematology
#2052: Oncologie Médicale
001:Oncologie Médicale
032005:Oncologie Médicale
0501: Clinique d'Oncologie Médicale
0501: Oncologie
0505 Oncologie Médicale
1001:Nucleair Medicine
1108: Hematologie
1602: Hématologie
303: Hematologie
303: Oncologie Médicale
32004: Oncologie Médicale
Chemotherapy
Chirurgie gynécologique
Clinical Hematology
Clinical Trial Conduct Unit
Clinical Trial Conduct Unit (Completed) / Medicine Oncology (Incomplete)
Clinical Trials Conduct Unit
Clinique d'Oncologie Médicale
CTSU ATPT and Medical Oncology
Departement of Hematology
Department of Gastrointestinal Oncology
Department of Haematology
Department of Hematology
Department of Medical Oncology
Department of Oncology
Dept of gastroenterology/hepatopancreatology/digestive oncology
Dept of Medical Oncology
Dept. of Medical Oncology
Digestive Oncology
Gastro-enterology
Gastro-intestinal Medical Oncology
Gastroenterology
GastroIntestinal Medical Oncology
Gynecologic Oncology
Haematology
Hématologie
Hematology
Hematology department
Infectiology
Infectious disease
Infectious diseases
Institut Jules Bordet
Lung Oncology
Medical Oncology
Medical Oncology - GI department
Medical Oncology / Clinical Trials Conduct Unit
Medical oncology department
MEDICAL ONCOLOGY/ HEAD OF CTCU
Medicine Oncology
Medische Oncologie
N/A
NA
Nucleaire geneeskunde
Nuclear medicine
Oncolgy
Oncologie
Oncologie digestive
Oncologie médicale
Oncology
Oncology department
Palliative care
PHU-Digestive Oncology Department
Pneumology
Radiation oncology
Radiotherapy
Radiotherapy-Oncology
Research, Medical oncology
Surgical Oncology
Thoracic Oncology
Thoracic Oncology Clinic
Treatment centre

Clinical trials at this site (248)

Search interface

A phase 1/2 open-label, multicenter study to assess the safety, pharmacokinetics and anti-tumor activity of GTAEXS617 in patients with advan… Recruiting

2023-508227-13-00 Advanced solid tumors 7 2023-06-19
Benefit of transplantation after Complete Response In Patients with T-cell lymphoma Recruiting

2022-501710-62-02 Peripheral T-cell lymphoma (PTCL) 6 2023-06-07
Maintenance Pembrolizumab at Usual or Low doSE in non-squamous lung cancer: a non-inferiority study Recruiting

2023-503481-23-00 Maintenance treatment in metastatic non-squamous lung c 5 2023-03-20
Phase I/Ib clinical trial of PM54 in Advance Solid Tumors patients Recruiting

2023-508644-22-00 Advance Solid Tumors 7 2023-02-28
Preoperative treatment with mFOLFIRINOX (or Gem-Nab-P) +/- isotoxic high-dose Stereotactic Body Radiation Therapy (iHD-SBRT) for borderline … Recruiting

2022-501181-22-01 Pancreatic adenocarcinoma 4 2023-02-06
A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokine… Recruiting

2023-506818-45-00 Solid tumors that have a high incidence of Homologous R 7 2022-12-13
A multicenter phase 1/2 study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas Recruiting

2024-514826-22-00 Part A: Patients with advanced solid tumors or lymphoma 7 2022-12-05
A study of tucatinib with trastuzumab and mFOLFOX6 versus standard of care treatment in first-line HER2+ metastatic colorectal cancer Recruiting

2024-514180-25-00 unresectable or metastatic HER2+ colorectal cancer 5 2022-11-21
Phase 1/1b study to assess the drug OBT076 in patients with recurrent and/or metastatic CD205-positive solid tumors Recruiting

2024-511884-27-00 CD205+ve recurrent and/or metastatic tumor types includ 3 2022-11-09
A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination… Recruiting

2023-503442-30-00 Multiple Myeloma 5 2022-10-14
A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or … Recruiting

2023-506517-22-00 Advanced or Metastatic Colorectal Cancer 9 2022-08-31
Immunological variables associated to ICI toxicity in cancer patients Recruiting

2023-505360-11-00 solid tumour 4 2022-08-18
RAINBO: Refining Adjuvant treatment IN endometrial cancer Based On molecular features, TransPORTEC platform trials (MMRd-GREEN) Recruiting

2023-503267-42-00 Patients with a histological diagnosis of mismatch- rep 5 2022-06-10
Metastasis-directed therapy, whether or not in combination with hormone therapy, in patients with prostate cancer recurrence after initial t… Recruiting

2022-502373-42-00 Oligorecurrent hormone-sensitive prostate cancer patien 5 2022-04-25
Beamion LUNG-1: A study to test different doses of zongertinib in people with different types of advanced cancer (solid tumours with changes… Recruiting

2024-511246-39-00 Solid tumours with HER2 aberrations 1 2021-07-27
Study evaluating near-infrared imaging coupled with indocyanine green for intraoperative monitoring of resection margins in ENT surgery Recruiting

2022-502737-26-00 epidermoid carcinoma 4 2020-12-15
Allogeneic hematopoietic cell transplantation from HLA-matched donor after Flu-Mel-PTCy versus Flu-Mel-ATG reduced-intensity conditioning: a… Recruiting

2024-518568-11-00 Hematological malignancies confirmed histologically: - 4 2019-02-04
Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting

2023-504201-36-00 Defined by parent protocol. The study will enroll all a 10 2018-12-21
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (petosemtamab) as single agent or in combination in advanced solid … Recruiting

2024-513627-16-01 Colorectal cancer metastatic 7 2018-03-28
GRAALL2014 Recruiting

2024-516103-16-00 Acute Lymphoblastic Leukemia (ALL) in younger adults (1 4 2015-12-04
A study of BMS-986504 in combination with Nab-p/Gem versus placebo in combination with Nab-p/Gem in untreated metastatic PDAC with homozygou… Ended

2025-522598-12-00 Untreated Metastatic Pancreatic Ductal Adenocarcinoma 10 2025-12-17
A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended

2024-519773-19-00 Gastroesophageal Junction Adenocarcinoma 5 2025-07-31
Study of Zelenectide Pevedotin in Participants with Advanced Breast Cancer Ended

2024-517868-33-00 NECTIN4 Amplified Advanced Breast Cancer 4 2025-06-12